Patent Trial and Appeal Board

Sarepta Therapeutics Inc (NASDAQ: SRPT) announced Tuesday that the Patent Trial and Appeal Board issued two favorable decisions for Sarepta which refused BioMarin Pharmaceutical Inc. (NASDAQ: BMRN)'s claims. In a report, Brian Skorney of Baird suggested the PTAB's ruling implies Sarepta...

On August 24, the Patent Trial and Appeal Board (PTAB) invalidated Teva Pharmaceutical Industries Ltd (ADR) (NYSE: TEVA) ‘250 and ‘450 mg/mL Copaxone patents. This week, the PTAB invalidated the remaining ‘302 patent as well. Where do these PTAB decisions leave investors?...